The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment
Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now bee...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in h...
Mutations of RAS oncogenes are responsible for about 30% of all human cancer types, including pancre...
RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-regulated binary on-off switches, w...
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of...
KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all...
RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inh...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
<p>The RAS family is a group of small GTPases that can become constitutively activated by point muta...
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly hom...
The RAS gene family, responsible for signal transduction within the mitogen activated protein kinase...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
Targeting of oncogenic driver mutations with small-molecule inhibitors resulted in powerful treatmen...
Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now bee...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in h...
Mutations of RAS oncogenes are responsible for about 30% of all human cancer types, including pancre...
RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-regulated binary on-off switches, w...
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of...
KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all...
RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inh...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
<p>The RAS family is a group of small GTPases that can become constitutively activated by point muta...
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly hom...
The RAS gene family, responsible for signal transduction within the mitogen activated protein kinase...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
Targeting of oncogenic driver mutations with small-molecule inhibitors resulted in powerful treatmen...
Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now bee...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
DOI
Add to ORKG